Discover
TNYA
Tenaya Therapeutics, Inc.
0.75
2 x 0.52
2 x 0.96
bid
ask
+
0.01
0.92%
2 @ 04:00 PM
0.75 +0.00 (0.00%)
| Ytd | 4.76% | |
| 1y | 21.68% |
0.72
day range
0.75
0.53
52 week range
2.35
| Open | 0.74 | Prev Close | 0.74 | Low | 0.72 | High | 0.75 | Mkt Cap | 161.86M |
| Vol | 1.24M | Avg Vol | 3.61M | EPS | -0.44 | P/E | N/A | Forward P/E | -1.28 |
| Beta | 2.35 | Short Ratio | 2.31 | Inst. Own | 73.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 0.77 | 200-d Avg | 0.98 | 1yr Est | 18.50 |
| Income Statement | |||
| Total Revenue | 225.00K | ||
| Revenues (USD) | 225.00K | ||
| Gross Profit | 225.00K | ||
| Operating Expenses | 20.29M | ||
| Research and Development Expense | 14.84M | ||
| Selling, General and Administrative Expense | 5.45M | ||
| Operating Income | -20.07M | ||
| Net Income | -19.27M | ||
| Net Income Common Stock | -19.27M | ||
| Net Income Common Stock (USD) | -19.27M | ||
| Consolidated Income | -19.27M | ||
| Earnings per Basic Share | -0.09 | ||
| Earnings per Basic Share (USD) | -0.09 | ||
| Earnings per Diluted Share | -0.09 | ||
| Earning Before Interest & Taxes (EBIT) | -19.27M | ||
| Earning Before Interest & Taxes (USD) | -19.27M | ||
| Weighted Average Shares | 216.88M | ||
| Weighted Average Shares Diluted | 216.88M | ||
| Balance Sheet | |||
| Cash and Equivalents | 80.89M | ||
| Cash and Equivalents (USD) | 80.89M | ||
| Trade and Non-Trade Receivables | 10.63M | ||
| Current Assets | 96.56M | ||
| Property, Plant & Equipment Net | 34.72M | ||
| Total Assets | 135.07M | ||
| Debt Current | 3.12M | ||
| Total Debt | 10.12M | ||
| Current Liabilities | 16.78M | ||
| Debt Non-Current | 7.00M | ||
| Total Liabilities | 28.88M | ||
| Accumulated Retained Earnings (Deficit) | -624.28M | ||
| Shareholders Equity | 106.19M | ||
| Shareholders Equity (USD) | 106.19M | ||
| Assets Non-Current | 38.51M | ||
| Total Debt (USD) | 10.12M | ||
| Liabilities Non-Current | 12.10M | ||
| Trade and Non-Trade Payables | 1.91M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.42M | ||
| Net Cash Flow from Financing | -415.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -19.66M | ||
| Capital Expenditure | -11.00K | ||
| Net Cash Flow from Investing | -11.00K | ||
| Net Cash Flow from Operations | -19.23M | ||
| Share Based Compensation | 2.20M | ||